REGENXBIO Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- REGENXBIO Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $18.88M.
- REGENXBIO Inc. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- REGENXBIO Inc. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $0.00.
- REGENXBIO Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $131.07M.
- REGENXBIO Inc. stock issued during period, value, new issues for fiscal 2021 was $216.06M.
- REGENXBIO Inc. stock issued during period, value, new issues for fiscal 2018 was $189.10M, a 132.05% increase from fiscal 2017.
- REGENXBIO Inc. stock issued during period, value, new issues for fiscal 2017 was $81.49M.
- REGENXBIO Inc. stock issued during period, value, new issues for fiscal 2015 was $145.18M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $18.88M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | |
| 2024-03-31 | $131.07M 10-Q · filed 2024-05-08 | |
| 2023-09-30 | $4.87M 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $216.06M 10-K · filed 2024-02-27 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | |
| 2021-03-31 | $216.06M 10-Q · filed 2022-05-04 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $189.10M 10-K · filed 2021-03-01 |
| 2018-09-30 | $189.10M 10-Q · filed 2019-11-05 | |
| 2017-12-31 | $81.49M 10-K · filed 2020-02-26 | |
| 2015-12-31 | $145.18M 10-K · filed 2018-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |